Precision medicine in the age of big data: The present and future role of large‐scale unbiased sequencing in drug discovery and development
Authors:
- 19 December 2015
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 99 (2) , 198-207
Abstract
High throughput molecular and functional profiling of patients is a key driver of precision medicine. DNA and RNA characterization has been enabled at unprecedented cost and scale through rapid, disruptive progress in sequencing technology, but challenges persist in data management and interpretation. We analyze the state‐of‐the‐art of large‐scale unbiased sequencing in drug discovery and development, including technology, application, ethical, regulatory, policy and commercial considerations, and discuss issues of LUS implementation in clinical and regulatory practice.Keywords
This publication has 67 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- An integrated map of genetic variation from 1,092 human genomesNature, 2012
- Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT ProjectClinical Pharmacology & Therapeutics, 2012
- Performance comparison of whole-genome sequencing platformsNature Biotechnology, 2011
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion OncogeneJAMA, 2011
- Assembly algorithms for next-generation sequencing dataGenomics, 2010
- Genetic diagnosis by whole exome capture and massively parallel DNA sequencingProceedings of the National Academy of Sciences, 2009
- Personalized Medicine and Inhibition ofEGFRSignaling in Lung CancerNew England Journal of Medicine, 2009
- Expression profiling of microRNAs by deep sequencingBriefings in Bioinformatics, 2009